Ibuprofen - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for ibuprofen and what is the scope of patent protection?
Ibuprofen
is the generic ingredient in forty-four branded drugs marketed by Glaxosmithkline, Amneal Pharms, Ascent Pharms Inc, Aurobindo Pharma Ltd, Bionpharma, Contract Pharmacal, Humanwell Puracap, Marksans Pharma, P And L Dev Llc, Sofgen Pharms, Strides Pharma, Bayer, Cumberland Pharms, J And J Consumer Inc, Guardian Drug, L Perrigo Co, Taro Pharms, Tris Pharma Inc, Mcneil, Moberg Pharma North, Perrigo, Abbott, Actavis Mid Atlantic, Akorn, Aptapharma Inc, Arise, P And L, Padagis Us, Taro, Mcneil Consumer, Mcneil Ped, Lederle, Basf, Alra, Pliva, Alkem Labs Ltd, Amneal Pharms Ny, Ani Pharms, Aurobindo Pharma, Avema Pharma, Dr Reddys La, Dr Reddys Labs Inc, Granules, Granules India, Halsey, Ivax Sub Teva Pharms, Leiner, LNK, Merro Pharm, Mylan, Northstar Hlthcare, OHM, Ohm Labs, Par Pharm, Perrigo R And D, Purepac Pharm, Rising, Sandoz, Shandong Xinhua, Sun Pharm Industries, Sunshine, Superpharm, Teva, Ultratab Labs Inc, Vintage Pharms, Watson Labs, Yichang Humanwell, Bristol Myers, Xgen Pharms, Recordati Rare, Forest Labs, Actavis Elizabeth, Barr Labs Inc, and Dr Reddys Labs Ltd, and is included in two hundred and twenty-four NDAs. There are eleven patents protecting this compound. Additional information is available in the individual branded drug profile pages.Ibuprofen has sixty-five patent family members in nineteen countries.
There are sixty-four drug master file entries for ibuprofen. Two hundred and thirty-five suppliers are listed for this compound.
Summary for ibuprofen
International Patents: | 65 |
US Patents: | 11 |
Tradenames: | 44 |
Applicants: | 74 |
NDAs: | 224 |
Drug Master File Entries: | 64 |
Finished Product Suppliers / Packagers: | 235 |
Raw Ingredient (Bulk) Api Vendors: | 200 |
Clinical Trials: | 842 |
Patent Applications: | 7,251 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price trends for ibuprofen |
Drug Sales Revenues: | Drug sales revenues for ibuprofen |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ibuprofen |
What excipients (inactive ingredients) are in ibuprofen? | ibuprofen excipients list |
DailyMed Link: | ibuprofen at DailyMed |
Recent Clinical Trials for ibuprofen
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
United States Department of Defense | Phase 4 |
Mclean Hospital | Phase 4 |
University of Miami | Phase 2 |
Pharmacology for ibuprofen
Drug Class | Nonsteroidal Anti-inflammatory Drug |
Mechanism of Action | Cyclooxygenase Inhibitors |
Medical Subject Heading (MeSH) Categories for ibuprofen
Anatomical Therapeutic Chemical (ATC) Classes for ibuprofen
Paragraph IV (Patent) Challenges for IBUPROFEN
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
PEDIATRIC ADVIL | Oral Suspension | ibuprofen | 50 mg/1.25 mL | 020812 | 1 | 2007-06-29 |
US Patents and Regulatory Information for ibuprofen
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vintage Pharms | IBUPROFEN | ibuprofen | TABLET;ORAL | 072004-001 | Nov 18, 1987 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
L Perrigo Co | IBUPROFEN | ibuprofen | TABLET;ORAL | 077114-001 | Jul 18, 2005 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Basf | IBU | ibuprofen | TABLET;ORAL | 070083-001 | Feb 22, 1985 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Recordati Rare | NEOPROFEN | ibuprofen lysine | INJECTABLE;INTRAVENOUS | 021903-001 | Apr 13, 2006 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |
Strides Pharma | IBUPROFEN | ibuprofen | TABLET;ORAL | 070986-001 | Jul 25, 1986 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Aurobindo Pharma Ltd | IBUPROFEN | ibuprofen | TABLET;ORAL | 213794-002 | May 8, 2020 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ibuprofen
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Mcneil Ped | MOTRIN | ibuprofen | TABLET, CHEWABLE;ORAL | 020135-002 | Nov 16, 1994 | ⤷ Try a Trial | ⤷ Try a Trial |
Bionpharma | MIDOL LIQUID GELS | ibuprofen | CAPSULE;ORAL | 021472-001 | Oct 18, 2002 | ⤷ Try a Trial | ⤷ Try a Trial |
J And J Consumer Inc | JUNIOR STRENGTH MOTRIN | ibuprofen | TABLET, CHEWABLE;ORAL | 020601-003 | Nov 15, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
J And J Consumer Inc | CHILDREN'S MOTRIN | ibuprofen | TABLET, CHEWABLE;ORAL | 020601-001 | Nov 15, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
Glaxosmithkline | CHILDREN'S ADVIL | ibuprofen | SUSPENSION;ORAL | 019833-002 | Sep 19, 1989 | ⤷ Try a Trial | ⤷ Try a Trial |
J And J Consumer Inc | CHILDREN'S MOTRIN | ibuprofen | SUSPENSION/DROPS;ORAL | 020603-001 | Jun 10, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for ibuprofen
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Recordati Rare Diseases | Pedea | ibuprofen | EMEA/H/C/000549 Treatment of a haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age. |
Authorised | no | no | no | 2004-07-28 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for ibuprofen
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Brazil | PI1006222 | uso de ibuprofeno na redução de dor em pacientes humanos que são submetidos a cirurgia, uso de ibuprofeno na redução de dor cirúrgica em pacientes humanos e uso de ibuprofeno para melhorar o tempo ambulatorial após a operação em pacientes humanos que sorem procedimentos cirúrgicos ortopédicos | ⤷ Try a Trial |
Portugal | 2825039 | ⤷ Try a Trial | |
Australia | 2009350474 | Treating critically ill patients with intravenous ibuprofen | ⤷ Try a Trial |
China | 102791268 | Treating critically ill patients with intravenous ibuprofen | ⤷ Try a Trial |
Canada | 2767971 | TRAITEMENT A BASE D'IBUPROFENE PAR VOIE INTRAVEINEUSE (TREATING PATIENTS WITH INTRAVENOUS IBUPROFEN) | ⤷ Try a Trial |
Spain | 2694506 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:






Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.